• Autonomy (sponsor: Janssen): anti-tau antibody; monthly IV infusion in prodromal Alzheimer’s disease (MCI with evidence of tauopathy). PI: Pr Bernard Hanseeuw. Actively recruiting. https://clinicaltrials.gov/ct2/show/NCT04619420

• Skyline (sponsor: Roche): anti-amyloid antibody; bi-monthly subcutaneous injection of Gantenerumab in asymptomatic adults older than 60 with evidence of amyloidosis after blood test and PET scanning. PI: Pr Bernard Hanseeuw. Starting date: Summer 2022. https://clinicaltrials.gov/ct2/show/NCT05256134

• A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer’s Disease (AD) (NCT04867616) (PI: Rik Vandenberghe, UZ Leuven)
• A Study of JNJ-63733657 in Participants With Early Alzheimer’s Disease (Autonomy)(NCT04619420) (PI: Rik Vandenberghe, UZ Leuven)
• A Research Study Investigating Semaglutide in People With early Alzheimer’s Disease (EVOKE Plus) (NCT04777409) (PI: Rik Vandenberghe, UZ Leuven)
• Deudextromethorphan, A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6 DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type (Study nurse: 02/555 55 02)
• CN0080003, A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease (TargetTau-1) (Study nurse: 02/555 55 02)

Frontotemporal degeneration:

• Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM) (NCT04408625) (PI: Rik Vandenberghe, UZ Leuven)
• A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) (NCT04374136) (PI: Rik Vandenberghe, UZ Leuven)
• Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9) (NCT04931862) (PI: Rik Vandenberghe en Philip Van Damme, UZ Leuven)

• Fahr’s disease:

  • Treatment of ectopic celcification in Fahr’s disease or syndrome  (CALCIFADE)

 Neuromuscular Disease:

Pompe’s disease:

• Fase 3 studie met intraveneuze ATB200 en perorale AT2221 behandeling, bij de ziekte van Pompe (NCT04138277) (PI: Kristl Claeys, UZ Leuven) 
• Fase 3 studie met intraveneuze avalglucosidase-alfa of alglucosidase-alfa behandeling, bij de ziekte van Pompe (NCT02782741) (PI: Kristl Claeys, UZ Leuven) 
•  Register voor patiënten met de ziekte van Pompe (NCT00231400) (PI: Kristl Claeys, UZ Leuven) 
• Savant, Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting (Study nurse: 02/555 55 02)

Limb-girdle muscle dystrophy (LGMD):

• Natuurlijke verloop studie bij limb-girdle spierdystrofie type sarcoglycanopathieën (NCT04475926) (PI: Kristl Claeys, UZ Leuven) 

Mitochondrial myopathy:

• Fase 2/3 studie met perorale REN001 behandeling bij primaire mitochondriale myopathie (PMM) (NCT04535609) (PI: Kristl Claeys, UZ Leuven) 
• Fase 2/3 open label lange termijn studie met perorale REN001 behandeling bij primaire mitochondriale myopathie (NCT05267574) (PI: Kristl Claeys, UZ Leuven)
• Fase 3 studie met perorale KL1333 behandeling bij primaire mitochondriale myopathie (PMM) (NCT05650229) (PI: Kristl Claeys, UZ Leuven)
• Falcon, An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease. (Study nurse: 02/555 55 02)

transthyretine (TTR) polyneuropathy:

• Fase 3 studie met subcutane ALN-TTRSC02 behandeling, bij erfelijke transthyretine polyneuropathie (hATTR Amyloïdose) (NCT03759379) (PI: Kristl Claeys, UZ Leuven) 

Charcot-Marie-Tooth neuropathy (CMT):

• Fase 3 studie met perorale PXT3003 behandeling, bij Charcot-Marie-Tooth neuropathie Type 1A (CMT1A) (NCT04762758) (PI: Kristl Claeys, UZ Leuven) 

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP):

• Fase 2 studie met subcutane Efgartigimod behandeling, bij patiënten met CIDP (NCT04281472) (PI: Kristl Claeys, UZ Leuven) 
•  Fase 2 lange-termijn studie met subcutane Efgartigimod behandeling, bij patiënten met CIDP (NCT04280718) (PI: Kristl Claeys, UZ Leuven) 

Myasthenia gravis:

• Fase 3 studie met intraveneuze Nipocalimab behandeling, bij veralgemeende myasthenia gravis (NCT04951622) (PI: Kristl Claeys, UZ Leuven) 
•  Fase 3 studie met intraveneuze Efgartigimod behandeling, bij veralgemeende myasthenia gravis (NCT04980495) (PI: Kristl Claeys, UZ Leuven) 
•  Register voor patiënten met myasthenia gravis (NCT04176211) (PI: Kristl Claeys, UZ Leuven) 
• https://www.uzleuven.be/nl/neurologie/neuromusculair-referentiecentrum-nmrc/klinische-studies-neuromusculaire-ziekten/spierziekten-neuropathieen-en-myasthenia-gravis
• CLOU064O12301, Remibrutinib, A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis (gMG),followed by an open label extension phase (Study nurse: 02/555 55 02)

Inflammatoire myopathieën/Myositis:

• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (NCT05695950) (PI: Kristl Claeys, UZ Leuven)

• C0251006 (Pfizer), Active Idiopathic Inflammatory Myopathies (Including Dermatomyositis or Polymyositis), To evaluate the efficacy of PF-06823859 compared with placebo in reducing muscle symptoms in adult participants (aged ≥ 18 years) with active DM and PM (Study nurse: 02/555 55 02)

Spinale Musculaire Atropfie (SMA):

• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (NCT05695950) (PI: Kristl Claeys, UZ Leuven)

Fibrodysplasia ossificans progressiva (FOP):

• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (NCT05695950) (PI: Kristl Claeys, UZ Leuven)

Amyotrophic lateral sclerosis (ALS):

• A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis (ADORE) (2020-003376-40) (PI: Philip Van Damme, UZ Leuven) 
•  A study of BIIB067 when initiated in Clinically Presymptomatic Adults with a confirmed superoxide dismutase 1 mutation (ATLAS) (NCT04856982) (PI: Philip Van Damme, UZ Leuven) 
•  A study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) (COURAGE) (NCT04944784) (PI: Philip Van Damme, UZ Leuven) 
•  A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants with Fused in Sarcoma Mutations (FUS-ALS) (FUSION) (NCT04768972) (PI: Philip Van Damme, UZ Leuven) 
•  A multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) (MAGNET) (2020-000579-19) (PI: Philip Van Damme, UZ Leuven) 

Huntington’s disease:

• Enroll, A prospective Registry Study in a Global Huntington Disease (HD) Cohort (Study Nurse: 02/555.55.02)

Epilepsy:

• Multimodal profiling of people with epilepsy to determine which signals are clinically useful for long-term home monitoring (NCT04642105) (PI: Wim Van Paesschen, UZ Leuven)
• Marinus, Refractory status epilepticus A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus Ganaxolone 3 2022-502540-12 (Study nurse: 02/555 55 02)
• ULTRA, U002, Evaluation of the 24/7 EEG™ SubQ System for Ultra Long-Term Recording of Patients with Temporal Lobe Epilepsy (Study nurse: 02/555 55 02)
• BHV, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset Epilepsy (Study nurse: 02/555 55 02)

Multiple Sclerosis:

• Perseus, Tolebrutinib, A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis, (Study nurse: 02/555 55 02)
• Musicale, To describe the impact of ocrelizumab treatment using changes in overall SymptoMScreen score in RMS and PPMS patients (analysed separately) over a period of 4 years (Study nurse: 02/555 55 02)
• Musette, Ocrelizumab, This study will evaluate the efficacy, safety, and pharmacokinetics of a higher dose of ocrelizumab compared with the approved dose of ocrelizumab in patients with relapsing forms of multiple sclerosis (RMS). Specific objectives and corresponding endpoints for the study are outlined below.(Study nurse: 02/555 55 02)
• CLOU064C12301, Remibrutinib, A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with SEP,followed by extended treatment with open label remibrutinib (Study nurse: 02/555 55 02)
• CosMOG, Rozanolixizumab, A randomized, double-blind, placebo-controlled, Phase 3 study evaluating the efficacy and safety of rozanolixizumab in participants with myelin oligodendrocyte glycoprotein antibody-associated disease, (Study nurse: 02/555 55 02)

Stroke:

• Oceanic, Study to investigate the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) compared with placebo in participants after an acute noncardioembolic ischemic stroke or high-risk TIA, (Study nurse: 02/555 55 02)
• Cases, To assess the safety and efficacy of immediate cervical CAS during EVT in patients with acute ischemic stroke due to LVO with a high-grade stenosis >50% or occlusion of the ipsilateral cervical carotid artery (Study nurse: 02/555 55 02)
• Distals, Study to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in subjects presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management (Study nurse: 02/555 55 02)
• Bioxode, A study to evaluate the safety, tolerability and the effects of Ixodes ricinus-Contact Phase Inhibitor (Ir-CPI) in adult patients with spontaneous intracerebral haemorrhage (Study nurse: 02/555 55 02)
• Tecno, Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusions (Study nurse: 02/555 55 02)